 |
Prospector
Profile
07.1202
|
| |
| Jazz Pharmaceuticals, Inc. |
NAICS |
541710 |
| 3180 Porter Drive
Palo Alto, CA 94304 |
Description |
Biotechnology |
| (650) 496-3777 |
Employees |
185 |
| http://www.jazzpharmaceuticals.com/ |
Revenue |
(mil) |
44.8560 |
| |
Income |
(mil) |
-59.3910 |
| |
Assets |
(mil) |
214.5710 |
| |
Liability |
(mil) |
390.8600 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Jazz Pharmaceuticals, Inc. reported a net loss for the second quarter ended June 30, 2007 of $39.9 million, compared to a net loss of $24.1 million for the second quarter of 2006. Total revenues for the quarter ended June 30, 2007, were $14.3 million, compared to $11.1 million for the quarter ended June 30, 2006.
|
| |
|
Intellectual Property:
The Company's commercial success will depend on obtaining and maintaining patent protection and trade secret protection of product candidates, their use and the methods used to manufacture them, as well as successfully defending these patents against third party challenges. The Company also may rely on trade secrets and other unpatented proprietary information to protect technology. The FDA has granted orphan drug exclusivity for Xyrem until July 2009 for cataplexy in patients with narcolepsy, and until November 2012 for excessive daytime sleepiness in patients with narcolepsy. The Company has filed a patent application with claims covering the method for distributing sodium oxybate using a centralized distribution system. The Company uses Jazz Pharmaceuticals™, Xyrem®, Antizol®, Luvox® and the Jazz Pharmaceuticals logo as trademarks in the U.S. and other countries. It has licensed the right to use the registered trademarks Antizol® from Mericon Investment Group, Inc. and Luvox® from Solvay Pharmaceuticals, Inc. [SEC Filing S-1 05-31-07]
|
| |
|
Description:
The Company focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States.
|
| |
|
Officers:
Bruce C. Cozadd (Chair); Samuel R. Saks, M.D. (CEO & Dir.); Robert M. Myers (Pres.); Matthew K. Fust (SVP & CFO); Carol A. Gamble (SVP, Sec. & Gen. Counsel); Janne L.T. Wissel (SVP); Adam H. Clammer (Dir.); Samuel D. Colella (Dir.); Bryan C. Cressey (Dir.); Michael W. Michelson (Dir.); James C. Momtazee (Dir.); Kenneth W. O’Keefe (Dir.); Alan M. Sebulsky (Dir.); James B. Tananbaum, M.D. (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol JAZZ; NasdaqGM;
24,550,554 common shares outstanding as of July 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
